Cargando…

Retraction Note: MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia

Detalles Bibliográficos
Autores principales:	Xishan, Zhu, Ziying, Lin, Jing, Du, Gang, Liu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Retraction Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981588/ https://www.ncbi.nlm.nih.gov/pubmed/36864099 http://dx.doi.org/10.1038/s41598-023-30736-3

Ejemplares similares

MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia
por: Xishan, Zhu, et al.
Publicado: (2015)

Retraction Note: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
por: Wu, L. X., et al.
Publicado: (2020)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Expression of chronic myeloid leukemia oncogenes BCR-ABL (P210) and BCR-ABL (T315I) affect cellular and humoral innate immunity in Drosophila melanogaster
por: Abubaker, Dana, et al.
Publicado: (2022)

Retraction: MicroRNA-503 Acts as a Tumor Suppressor in Osteosarcoma by Targeting L1CAM
Publicado: (2022)

MicroRNA-217 Acts as a Tumor Suppressor and Correlates with the Chemoresistance of Cervical Carcinoma to Cisplatin [Retraction]
Publicado: (2023)

MicroRNA-200b Acts as a Tumor Suppressor in Osteosarcoma via Targeting ZEB1 [Retraction]
Publicado: (2021)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Statement of Retraction: Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia
Publicado: (2020)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan
por: Tabassum, Najia, et al.
Publicado: (2014)

Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia
por: Cabanas, Hélène, et al.
Publicado: (2018)

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia
por: Amin, Huma, et al.
Publicado: (2021)

Single amino acid–based PROTACs trigger degradation of the oncogenic kinase BCR–ABL in chronic myeloid leukemia (CML)
por: Zhang, Jianchao, et al.
Publicado: (2023)

Retraction: BRD7 Acts as a Tumor Suppressor Gene in Lung Adenocarcinoma
Publicado: (2023)

[Retracted] EVI‑1 acts as an oncogene and positively regulates calreticulin in breast cancer
por: Wu, Lei, et al.
Publicado: (2023)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013)

Pyrrolo-1,5-Benzoxazepines Induce Apoptosis in Chronic Myeloid Leukemia (CML) Cells by Bypassing the Apoptotic Suppressor BCR-ABL
por: Mc Gee, Margaret M., et al.
Publicado: (2001)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice
por: Vicente-Dueñas, Carolina, et al.
Publicado: (2012)

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
por: Samanta, A, et al.
Publicado: (2011)

Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
por: Sun, Xiaoyan, et al.
Publicado: (2016)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia
por: Molica, Matteo, et al.
Publicado: (2020)

p210(BCR‐ABL1)‐ Chronic myeloid leukemia presents with monocytosis
por: Wang, Xiaofei, et al.
Publicado: (2020)

Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
por: Yu, Chuanjiang, et al.
Publicado: (2020)

Retracted: Clinical Significance of EZH2 in Acute Myeloid Leukemia
por: Intelligence and Neuroscience, Computational
Publicado: (2023)

microRNA-628 Inhibits the Proliferation of Acute Myeloid Leukemia Cells by Directly Targeting IGF-1R [Retraction]
Publicado: (2021)

New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2015)

Retraction: PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation
por: Ma, Qiang, et al.
Publicado: (2018)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases
por: Huang, Ningshu, et al.
Publicado: (2018)

The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere length in chronic myeloid leukemia
por: Deręgowska, Anna, et al.
Publicado: (2023)

c-Fos and Dusp1 confer non-oncogene addiction in BCR-ABL induced leukemia
por: Kesarwani, Meenu, et al.
Publicado: (2017)

Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia
Publicado: (1989)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_la2nmictgllaoadf0pnufr129j